Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy

被引:39
作者
Pang, Lu [1 ]
Zhang, Ai-Min [2 ]
Li, Hai-Xia [1 ]
Du, Jia-Lin [1 ]
Jiao, Li-Li [1 ]
Duan, Nan [1 ]
Liu, Yi [1 ]
Yu, Dan [1 ]
机构
[1] Peking Univ, Dept Clin Lab, Hosp 1, Beijing, Peoples R China
[2] Tianjin Nankai Hosp, Dept Clin Lab, Tianjin, Peoples R China
关键词
glomerular PLA2R deposition; membranous nephropathy; serum anti-PLA2R antibody; PHOSPHOLIPASE-A2; RECEPTOR; AUTOANTIBODIES;
D O I
10.1097/MD.0000000000007218
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
M-type phospholipase A2 receptor (PLA2R) is the major target antigen in primary membranous nephropathy (PMN). Previous studies have evaluated the diagnostic value of serum anti-PLA2R antibody. However, the correlation of serum anti-PLA2R antibody and glomerular PLA2R deposition, and their association with clinical characteristics need to be further evaluated. A total of 136 patients were involved as inception group because serum anti-PLA2R antibody and glomerular PLA2R antigen were simultaneously measured. We examined serum anti-PLA2R antibody by ELISA and glomerular PLA2R deposition by immunofluorescence assay. Positive serum anti-PLA2R antibody and glomerular PLA2R deposition were seen in 58.8% (80/136) and 95.6% (130/136) patients, respectively (P <.001). Proteinuria, serum total protein, serum albumin, serum creatinine, and estimated glomerular filtration rate (eGFR) had significant differences between patients with serum anti-PLA2R antibody and those without. Serum anti-PLA2R antibody levels were correlated with serum albumin, serum creatinine, eGFR, and proteinuria. Glomerular PLA2R deposition intensities were weakly correlated with proteinuria. Unexpectedly, there was a positive correlation rather than a negative correlation between glomerular PLA2R deposition intensity and eGFR. In conclusion, serum anti-PLA2R antibody is more closely correlated with disease activity and renal function than glomerular PLA2R deposition.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] The characters of antibodies against PLA2R in healthy individuals and in the patient with PLA2R associated membranous nephropathy
    Cheng, Yan-jiao
    Wang, Miao
    Wang, Jia
    Cui, Zhao
    Zhao, Ming-hui
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [32] The characters of antibodies against PLA2R in healthy individuals and in the patient with PLA2R associated membranous nephropathy
    Yan-jiao Cheng
    Miao Wang
    Jia Wang
    Zhao Cui
    Ming-hui Zhao
    European Journal of Medical Research, 28
  • [33] The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery
    Van de Logt, Anne-Els
    Fresquet, Maryline
    Wetzels, Jack F.
    Brenchley, Paul
    KIDNEY INTERNATIONAL, 2019, 96 (06) : 1292 - 1302
  • [34] Serum PLA2R antibody as a predictive biomarker for venous thromboembolism risk in primary membranous nephropathy
    Li, Jiayi
    Wang, Xu
    Jiang, Shimin
    Li, Wenge
    MEDICINA CLINICA, 2023, 161 (10): : 417 - 421
  • [35] IgA nephropathy associated with anti-PLA2R antibody positive: a case report
    Xiao, Qian
    Li, Qiu-yue
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (11) : 3043 - 3044
  • [36] Monoclonal Anti-PLA2R and Recurrent Membranous Nephropathy: Another Piece of the Puzzle
    Beck, Laurence H., Jr.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (12): : 1911 - 1913
  • [37] Nomogram for thromboembolic events in primary membranous nephropathy associated with PLA2R antibody
    Zihan Zhai
    Yanhong Guo
    Lu Yu
    Yulin Wang
    Liuwei Wang
    Qiuhong Li
    Yapei Yuan
    Lin Tang
    Scientific Reports, 15 (1)
  • [38] Anti-PLA2R antibody measured by ELISA predicts the risk of vein thrombosis in patients with primary membranous nephropathy
    Zhu, Huizi
    Xu, Liang
    Liu, Xiang
    Liu, Bing
    Zhai, Chunjuan
    Wang, Rong
    Yang, Xiaowei
    RENAL FAILURE, 2022, 44 (01) : 594 - 600
  • [39] Efficacy and Safety of Different Immunosuppressive Therapies in Patients With Membranous Nephropathy and High PLA2R Antibody Titer
    Deng, Le
    Huang, Qipeng
    Wang, Jiang
    Luo, Kaiping
    Liu, Jiarong
    Yan, Wenjun
    Jiang, Fang
    Xu, Gaosi
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [40] Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels
    Xue, Cheng
    Wang, Jian
    Pan, Jinyan
    Liang, Congdie
    Zhou, Chenchen
    Wu, Jun
    Song, Shuwei
    Cui, Linlin
    Zhang, Liming
    Liu, Yawei
    Dai, Bing
    BMC NEPHROLOGY, 2023, 24 (01)